ClinicalTrials.gg
CompletedNCT00357110@FAMEUpdated Dec 21, 2010Results posted

Anastrozole and Fulvestrant Compared to Anastrozole as Adjuvant Treatment of Postmenopausal Patients With Breast Cancer

A Phase 2 interventional study of Fulvestrant and Anastrozole in Breast Cancer, sponsored by AstraZeneca. Completed at 25 sites in 3 countries. Open to female participants. Per ClinicalTrials.gov, last updated 2010-12-21.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
13
Allocation
Randomized
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 95 studies testing fulvestrant in Breast Neoplasms — 13 open to participants now, 23 under way, 5 of them phase 3. Fulvestrant · Breast Neoplasms.

Enrollment
78th of 94
13 · median 71
Started
2006
with 4 others
Phase 2
59 of 95
8 open now
Registered
24th of 95
by date
Lead sponsor
18 of 95
AstraZeneca

Among the 95 studies testing fulvestrant in Breast Neoplasms, this one is the 78th largest by enrollment of the 94 interventional ones that give a count, is one of 5 that started in 2006, is one of 59 in phase 2, and was the 24th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

13 of the 95 studies testing fulvestrant in Breast Neoplasms are open now, in 7 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About fulvestrant

Fulvestrant: first FDA approval 2002 (FASLODEX), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 95 studies testing fulvestrant in Breast Neoplasms, or all of them as a file.
02

Study summary

Purpose is to compare the frequency of events (presence of Disseminated Tumour Cells, clinical recurrence and/or death) after 1 and 2 years of adjuvant treatment with anastrozole and fulvestrant or anastrozole alone in patients with early breast cancer.

03

Conditions studied

  • Breast Cancer

Keywords

  • Breast neoplasms
  • breast cancer
  • early breast cancer
  • oncology
  • cancer
  • breast cancer micrometastasis
  • fulvestrant
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • women with hormone receptor-positive early breast cancer and a positive Disseminated Tumour Cell immunocytochemical result from bone marrow aspiration prior to randomisation

Exclusion criteria

Exclusion Criteria:

  • Inflammatory and/or breast cancer.
  • Current or previous within previous 5 years (other than Breast cancer or adequately treated non-melanoma skin cancer or in-situ cervical cancer).
  • History of bleeding diathesis.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
13 participants (actual)

Study arms

  • Active comparator
    1

    Anastrozole monotherapy

    Drug: Anastrozole

  • Experimental
    2

    Anastrozole + Fulvestrant

    Drug: Fulvestrant · Drug: Anastrozole

Interventions

  • intramuscular injection

    Also known as: Faslodex, ZD9238

  • 1 mg oral tablet

    Also known as: Arimidex, ZD1033

06

What researchers measure

Primary outcomes

  1. Patients Event-free at 12 Months (Where Event = Death (From Any Cause), Disseminated Tumour Cells (DTC) Positive at 12 Months or Clinical Disease Recurrence)

    Number of patients event-free

    Time frame: 12 month period following randomisation

07

Results

Posted Jan 22, 2010

Participant flow

Participant flow — Overall Study
MilestoneFulvestrant + AnastrozoleAnastrozole
Started67
Completed12
Not completed55
Withdrew: Early study termination55

Outcome measures

PrimaryPatients Event-free at 12 Months (Where Event = Death (From Any Cause), Disseminated Tumour Cells (DTC) Positive at 12 Months or Clinical Disease Recurrence)

Number of patients event-free

Time frame:
12 month period following randomisation
Reported as:
Number · Participants
Patients Event-free at 12 Months (Where Event = Death (From Any Cause), Disseminated Tumour Cells (DTC) Positive at 12 Months or Clinical Disease Recurrence)
ParticipantsFulvestrant + AnastrozoleAnastrozole
Patients Event-free at 12 Months (Where Event = Death (From Any Cause), Disseminated Tumour Cells (DTC) Positive at 12 Months or Clinical Disease Recurrence)67

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Fulvestrant + Anastrozole—1/6 (16.7%)5/6 (83.3%)
Anastrozole—2/7 (28.6%)5/7 (71.4%)
Most frequent serious events
Most frequent serious events
EventFulvestrant + AnastrozoleAnastrozole
Varicose VeinVascular disorders1/60/7
GoitreEndocrine disorders0/61/7
Haemorrhoid OperationGastrointestinal disorders0/61/7
SciaticaNervous system disorders0/61/7
Renal FailureRenal and urinary disorders0/61/7
Most frequent other events
Showing 10 of 37
Most frequent other events
EventFulvestrant + AnastrozoleAnastrozole
InsomniaPsychiatric disorders3/60/7
ArthralgiaMusculoskeletal and connective tissue disorders2/62/7
FlushingVascular disorders2/61/7
Unevaluable EventGeneral disorders2/61/7
AnorexiaMetabolism and nutrition disorders2/60/7
Back PainMusculoskeletal and connective tissue disorders1/60/7
Muscular WeaknessMusculoskeletal and connective tissue disorders1/60/7
Musculoskeletal Chest PainMusculoskeletal and connective tissue disorders1/60/7
Hot FlushVascular disorders1/61/7
FatigueGeneral disorders1/61/7

Baseline characteristics

Age Continuous
Age Continuous(age in years at baseline)Fulvestrant + AnastrozoleAnastrozoleTotal
Mean60.5 ± 5.463.4 ± 3.562.1 ± 4.5
Sex: Female, Male
Sex: Female, Male(Participants)Fulvestrant + AnastrozoleAnastrozoleTotal
Female6713
Male000
08

Study locations

25 sites
  • Research Site
    Feldkirch, Austria
  • Research Site
    Graz, Austria
  • Research Site
    Innsbruck, Austria
  • Research Site
    Klagenfurt, Austria
  • Research Site
    Leoben, Austria
  • Research Site
    Linz, Austria
  • Research Site
    Salzburg, Austria
  • Research Site
    St. Veit, Austria
  • Research Site
    Wiener Neustadt, Austria
  • Research Site
    Wien, Austria
  • Research Site
    Bayreuth, Germany
  • Research Site
    Essen, Germany
  • Research Site
    Hamburg-Eppendorf, Germany
  • Research Site
    Heidelberg, Germany
  • Research Site
    Munich, Germany
  • Research Site
    Rostock, Germany
  • Research Site
    Tubingen, Germany
  • Research Site
    Drammen, Norway
  • Research Site
    Fredrikstad, Norway
  • Research Site
    Kristiansand, Norway
  • Research Site
    Oslo, Norway
  • Research SIte
    Porsgrunn, Norway
  • Research Site
    Stavanger, Norway
  • Research Site
    Tonsberg, Norway
  • Research Site
    Trondheim, Norway
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2006, a primary completion of Oct 2008 and a completion of Oct 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2010, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 20, 2006
First posted
Jul 27, 2006
Start
Apr 2006
Primary completionActual
Oct 2008
CompletionActual
Oct 2008
Results first posted
Jan 22, 2010
Last update
Dec 21, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 21, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00357110
Lead sponsor
AstraZeneca
First posted
Jul 27, 2006
Start date
Apr 2006
Primary completion
Oct 2008
Completion
Oct 2008
Results posted
Jan 22, 2010
Last update
Dec 21, 2010

Study contacts

Breast Cancer Established Brands Team Medical Science Director, MD
study director · AstraZeneca
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fulvestrant

Start the discussion